US 11,896,753 B2
Therapeutic compositions for viral-associated disease states and methods of making and using same
Carol A. Rae, Rapid City, SD (US); Jan Simoni, Rapid City, SD (US); Grace Simoni, Rapid City, SD (US); and John F. Moeller, Rapid City, SD (US)
Assigned to Immutrix Therapeutics, Inc., Rapid City, SD (US)
Filed by IMMUTRIX THERAPEUTICS, INC., Rapid City, SD (US)
Filed on Mar. 3, 2020, as Appl. No. 16/807,858.
Application 16/807,858 is a continuation of application No. 15/513,221, granted, now 10,617,813, previously published as PCT/US2015/052272, filed on Nov. 18, 2015.
Claims priority of provisional application 62/055,392, filed on Sep. 25, 2014.
Prior Publication US 2020/0197598 A1, Jun. 25, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61M 1/36 (2006.01); B01J 47/02 (2017.01); B01J 20/20 (2006.01); A61M 1/02 (2006.01); A61M 1/14 (2006.01)
CPC A61M 1/3679 (2013.01) [A61M 1/0281 (2013.01); A61M 1/14 (2013.01); A61M 1/3687 (2013.01); B01J 20/20 (2013.01); B01J 47/02 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method comprising:
contacting a bodily fluid with an adsorbent material consisting essentially of a synthetic carbon particle (SCP) to produce a first filtrate, wherein the bodily fluid comprises a level of disease mediators (y);
contacting the first filtrate with an adsorbent material consisting essentially of the SCP and an anion exchange resin where the weight ratio of SCP to anion exchange resin is in a range from 0.1:100 to 100:0.1 to produce a second filtrate;
contacting the second filtrate with an adsorbent material consisting essentially of the SCP and a cation exchange resin where the weight ratio of SCP to cation exchange resin is in a range from 0.1:100 to 100:0.1 to produce a third filtrate; and
administering the third filtrate to the subject.